NCT04109924 - TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions

Advanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaMetastatic Rectal AdenocarcinomaRecurrent Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaRecurrent Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Colorectal CarcinomaUnresectable Rectal Adenocarcinoma

Interventions

DRUG

Irinotecan

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

33612

Moffitt Cancer Center, Tampa

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER